GL-7190 is under clinical development by Gliknik and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GL-7190’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GL-7190 is under development for the treatment of immunological disorders like inflammation. It acts by targeting C1q.
Gliknik is a bio pharmaceutical company that develops therapies for patients suffering from cancer and immune disorders. The company’s pipeline products include biropepimut-S (GL-0817) and GL-2045. Its biropepimut-S is an engineered peptide immunomodulator targeted against important epitopes within the cancer protein MAGE-A3. Gliknik designs recombinant GL-2045 to mimic the structure and efficacy of the very small and variable portion of the pooled human blood product IVIG, which is an active fraction in treating autoimmune disorders. The company partners with pharmaceutical industries. Gliknik is headquartered in Baltimore, Maryland, the US.
For a complete picture of GL-7190’s drug-specific PTSR and LoA scores, buy the report here.